Arvinas (ARVN) Revenue Growth (3y) (2020 - 2026)
Arvinas (ARVN) Revenue Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | 50.07% |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | 7.94% |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | 4.47% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | 79.44% |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 54.05% |
| 10 | Arvinas | 530.56 Mn | -84.34 Mn | - | -21.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.70% |
| Dec 31, 2025 | -36.89% |
| Sep 30, 2025 | 8.07% |
| Jun 30, 2025 | -12.81% |
| Mar 31, 2025 | 92.42% |
| Dec 31, 2024 | 21.26% |
| Sep 30, 2024 | 122.47% |
| Jun 30, 2024 | 140.49% |
| Mar 31, 2024 | 66.31% |
| Dec 31, 2023 | -106.64% |
| Sep 30, 2023 | 65.76% |
| Jun 30, 2023 | 111.66% |
| Mar 31, 2023 | 73.34% |
| Dec 31, 2022 | 97.68% |
| Sep 30, 2022 | 3.38% |
| Jun 30, 2022 | 103.40% |
| Mar 31, 2022 | 87.56% |
| Dec 31, 2021 | 112.91% |
| Sep 30, 2021 | 40.19% |
| Jun 30, 2021 | 17.39% |